Department of Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY.
Ann Surg. 2021 Sep 1;274(3):e276-e281. doi: 10.1097/SLA.0000000000003632.
We aimed to clarify whether aggressive histology of papillary thyroid cancer (PTC) impacts overall survival (OS).
Aggressive variants of PTC (AVPTC) are associated with invasive features. However, their behavior in the absence of these features is not well characterized.
Patients treated from 2004 to 2015 for classic PTC (cPTC) or AVPTCs were identified from the National Cancer Database. Patients were further stratified based on presence of at least 1 invasive feature-extrathyroidal extension, multifocality, lymphovascular invasion, nodal or distant metastasis. Demographics, treatments, and OS were compared.
A total of 170,778 patients were included-162,827 cPTC and 7951 AVPTC. Invasive features were more prevalent in AVPTC lesions compared to cPTC (70.7% vs 59.7%, P < 0.001). AVPTC included tall cell/columnar cell (89.5%) and diffuse sclerosing (10.5%) variants. Patients with invasive features had worse OS irrespective of histology. Furthermore, when controlling for demographics, tumor size, and treatment variables in patients with noninvasive lesions, AVPTC histology alone was not associated with worse OS compared to cPTC (P = 0.209). In contrast, among patients who had at least 1 invasive feature, AVPTC histology was independently predictive of worse OS (P < 0.05) {TCV/Columnar hazard ratio [HR] 1.2; [95% confidence interval (CI) 1.1-1.3] and diffuse sclerosing HR 1.3; 95% CI 1.0-1.7]}. All invasive features, except multifocality, were independently associated with worse OS, with metastasis being the most predictive [HR 2.9 (95% CI 2.6-3.2) P < 0.001].
In the absence of invasive features, AVPTC histology has similar OS compared to cPTC. In contrast, diffuse sclerosing and tall cell/columnar variants are associated with worse OS when invasive features are present.
我们旨在阐明侵袭性甲状腺乳头状癌(PTC)的组织学是否影响总生存率(OS)。
PTC 的侵袭性变体(AVPTC)与侵袭性特征相关。然而,在没有这些特征的情况下,它们的行为尚不清楚。
从国家癌症数据库中确定了 2004 年至 2015 年期间接受经典 PTC(cPTC)或 AVPTCs 治疗的患者。根据是否存在至少 1 种侵袭性特征(甲状腺外延伸、多灶性、血管淋巴管侵犯、淋巴结或远处转移)对患者进行进一步分层。比较了人口统计学、治疗和 OS。
共纳入 170778 例患者,其中 162827 例为 cPTC,7951 例为 AVPTC。与 cPTC 相比,AVPTC 病变中侵袭性特征更为常见(70.7%比 59.7%,P<0.001)。AVPTC 包括高细胞/柱状细胞(89.5%)和弥漫性硬化(10.5%)变体。无论组织学如何,具有侵袭性特征的患者的 OS 较差。此外,在控制非侵袭性病变患者的人口统计学、肿瘤大小和治疗变量后,与 cPTC 相比,单独的 AVPTC 组织学与较差的 OS 无关(P=0.209)。相比之下,在至少有 1 种侵袭性特征的患者中,AVPTC 组织学是独立预测较差 OS 的因素(P<0.05){TCV/Columnar 风险比 [HR] 1.2;[95%置信区间 (CI) 1.1-1.3]和弥漫性硬化 HR 1.3;95% CI 1.0-1.7]}。除多灶性外,所有侵袭性特征均与较差的 OS 独立相关,转移是最具预测性的特征[HR 2.9(95% CI 2.6-3.2),P<0.001]。
在没有侵袭性特征的情况下,AVPTC 组织学与 cPTC 的 OS 相似。相比之下,当存在侵袭性特征时,弥漫性硬化和高细胞/柱状细胞变体与较差的 OS 相关。